<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom"><channel><title>Human Genome Sciences News Release</title><link>http://phx.corporate-ir.net/Phoenix.zhtml?c=83257&amp;p=irol-news</link><description>A Collection of Human Genome Sciences News Release</description><language>en-us</language><category>Uncategorized</category><lastBuildDate>Sun, 19 May 2013 05:23:07 GMT</lastBuildDate><item><title>GSK to acquire Human Genome Sciences for US$14.25 per share in cash</title><link>http://phx.corporate-ir.net/phoenix.zhtml?c=83257&amp;p=RssLanding&amp;cat=news&amp;id=1714929</link><description><![CDATA[
      
        GSK to acquire full ownership of BENLYSTA®,
        albiglutide and darapladib
      
      
        Acquisition will be accretive to GSK core earnings in 2013
      
      
        Tender offer amended to US$14.25 per share and extended until 27
        July 2012
      
    
    LONDON--(BUSINESS WIRE)--Jul. 16, 2012--
      GlaxoSmithKline plc (LSE: GSK) and Human Genome Sciences (NASDAQ: HGSI)
      today announced that the companies have entered into a definitive
      agreement under which GSK will acquire HGS for US$14.25 per share in
      cash. The transaction values HGS at approximately US$3.6 billion on an
      equity basis, or approximately US$3 ...]]></description><category>Uncategorized</category><guid isPermaLink="false">1714929_NEWS</guid><pubDate>Mon, 16 Jul 2012 13:15:36 GMT</pubDate></item><item><title>FYI From Human Genome Sciences: GlaxoSmithKline Announces Positive Data from Harmony 8 Phase 3 Trial and Completion of Clinical Registration Package for Albiglutide in Type 2 Diabetes</title><link>http://phx.corporate-ir.net/phoenix.zhtml?c=83257&amp;p=RssLanding&amp;cat=news&amp;id=1713861</link><description><![CDATA[    ROCKVILLE, Md.--(BUSINESS WIRE)--Jul. 11, 2012--
      Attached is a press
      release issued earlier today by GlaxoSmithKline, announcing
      that data have been received from the Phase 3 Harmony 8 study and from
      the event-driven meta-analysis for assessment of cardiovascular safety
      conducted across the albiglutide clinical program in type 2 diabetes.
      These data are the final elements required to complete the clinical
      registration package.
    

      Albiglutide, an investigational once-weekly glucagon-like peptide-1
      (GLP-1) receptor agonist, was created by HGS using its proprietary
      albumin-fusion technology, and was licensed to GSK i...]]></description><category>Uncategorized</category><guid isPermaLink="false">1713861_NEWS</guid><pubDate>Wed, 11 Jul 2012 15:53:11 GMT</pubDate></item><item><title>Human Genome Sciences Announces Resubmission of Raxibacumab BLA to FDA</title><link>http://phx.corporate-ir.net/phoenix.zhtml?c=83257&amp;p=RssLanding&amp;cat=news&amp;id=1713040</link><description><![CDATA[
      
        FDA acknowledges receipt and sets PDUFA action date of December 15,
        2012
      
    
    ROCKVILLE, Md.--(BUSINESS WIRE)--Jul. 10, 2012--
      Human Genome Sciences, Inc. (Nasdaq: HGSI) announced today that the U.S.
      Food and Drug Administration (FDA) has acknowledged receipt of the
      resubmission of the Biologics License Application (BLA) for raxibacumab,
      a treatment for inhalational anthrax, and has established December 15,
      2012 as the Prescription Drug User Fee Act (PDUFA) action date.
    

      The FDA has deemed the resubmission a complete, class 2 response to its
      November 14, 2009 complete response letter, which reque...]]></description><category>Uncategorized</category><guid isPermaLink="false">1713040_NEWS</guid><pubDate>Tue, 10 Jul 2012 11:00:40 GMT</pubDate></item><item><title>Human Genome Sciences Responds To GSK Extension of Unsolicited Tender Offer</title><link>http://phx.corporate-ir.net/phoenix.zhtml?c=83257&amp;p=RssLanding&amp;cat=news&amp;id=1710620</link><description><![CDATA[    ROCKVILLE, Md.--(BUSINESS WIRE)--Jun. 29, 2012--
      Human Genome Sciences, Inc. (Nasdaq: HGSI) today issued the following
      statement regarding the extension by GlaxoSmithKline plc (GSK) of its
      unsolicited tender offer to acquire all the outstanding common shares of
      HGS at a price of $13.00 per share in cash and GSK’s statement that
      approximately 375,526 shares of HGS common stock have been tendered into
      their offer. HGS noted that less than one percent of its shares
      outstanding tendered into the GSK offer.
    

      The HGS Board of Directors has rejected GSK’s unsolicited $13.00 per
      share tender offer after determining, in consult...]]></description><category>Uncategorized</category><guid isPermaLink="false">1710620_NEWS</guid><pubDate>Fri, 29 Jun 2012 12:57:03 GMT</pubDate></item><item><title>Human Genome Sciences Announces July 16 as the Date for Submission of Definitive Acquisition Proposals</title><link>http://phx.corporate-ir.net/phoenix.zhtml?c=83257&amp;p=RssLanding&amp;cat=news&amp;id=1705555</link><description><![CDATA[    ROCKVILLE, Md.--(BUSINESS WIRE)--Jun. 15, 2012--
      Human Genome Sciences, Inc. (Nasdaq: HGSI) today announced that, in
      connection with its ongoing strategic alternative review process, it had
      previously set a bid date of July 16, 2012 for the submission of
      definitive proposals to acquire all outstanding common shares of HGS. In
      this regard, HGS yesterday sent a letter to GlaxoSmithKline (GSK) once
      again inviting GSK to participate in the ongoing process according to
      the same procedures previously established and to provide, by no later
      than July 16, 2012, GSK’s final bid terms, including a response to a
      draft agreement which wi...]]></description><category>Uncategorized</category><guid isPermaLink="false">1705555_NEWS</guid><pubDate>Fri, 15 Jun 2012 04:01:42 GMT</pubDate></item><item><title>FYI from Human Genome Sciences: GlaxoSmithKline Announces New Data from Phase 3 Studies of Once-Weekly Albiglutide in Type 2 Diabetes</title><link>http://phx.corporate-ir.net/phoenix.zhtml?c=83257&amp;p=RssLanding&amp;cat=news&amp;id=1703918</link><description><![CDATA[
      
        Detailed 52- and 32-week data from the first two Phase 3 studies of
        the investigational once-weekly glucagon-like peptide-1 (GLP-1)
        receptor agonist presented at ADA
      
    
    ROCKVILLE, Md.--(BUSINESS WIRE)--Jun. 9, 2012--
      Attached is a press
      release issued earlier this morning by GlaxoSmithKline,
      announcing that detailed findings from the Harmony 6 Phase 3 study
      comparing albiglutide to prandial insulin (Lispro), were presented today
      at the American Diabetes Association Meeting (ADA) in Philadelphia, USA,
      and show that the effect is maintained out to 52 weeks. Results from the
      Harmony 7 Phase 3 st...]]></description><category>Uncategorized</category><guid isPermaLink="false">1703918_NEWS</guid><pubDate>Sat, 09 Jun 2012 16:30:51 GMT</pubDate></item><item><title>Human Genome Sciences Responds to GSK Extension of Unsolicited Tender Offer</title><link>http://phx.corporate-ir.net/phoenix.zhtml?c=83257&amp;p=RssLanding&amp;cat=news&amp;id=1703775</link><description><![CDATA[    ROCKVILLE, Md.--(BUSINESS WIRE)--Jun. 8, 2012--
      Human Genome Sciences, Inc. (Nasdaq: HGSI) today issued the following
      statement regarding the extension by GlaxoSmithKline plc (GSK) of its
      unsolicited tender offer to acquire all the outstanding common shares of
      HGS at a price of $13.00 per share in cash and GSK’s statement that
      approximately 474,029 shares of HGS common stock have been tendered into
      their offer. HGS noted that less than one percent of its shares
      outstanding tendered into the GSK offer.
    

      The HGS Board of Directors has rejected GSK’s unsolicited $13.00 per
      share tender offer after determining, in consulta...]]></description><category>Uncategorized</category><guid isPermaLink="false">1703775_NEWS</guid><pubDate>Fri, 08 Jun 2012 13:25:18 GMT</pubDate></item><item><title>Human Genome Sciences Announces Multiple Abstracts Related to BENLYSTA® and Systemic Lupus Erythematosus to Be Presented at the 2012 EULAR Annual European Congress of Rheumatology</title><link>http://phx.corporate-ir.net/phoenix.zhtml?c=83257&amp;p=RssLanding&amp;cat=news&amp;id=1702845</link><description><![CDATA[    ROCKVILLE, Md.--(BUSINESS WIRE)--Jun. 5, 2012--
      Human Genome Sciences, Inc. (Nasdaq: HGSI) announced today that several
      abstracts related to BENLYSTA® (belimumab) and systemic lupus
      erythematosus (SLE) will be presented at the EULAR Annual European
      Congress of Rheumatology, being held in Berlin, Germany from June 6 to
      June 9, 2012. A total of seven abstracts – all posters – have been
      accepted for presentation, five clinical trial data abstracts and two
      health economics and outcomes research (HEOR) abstracts.
    

      Belimumab is the first in a drug class known as BLyS-specific
      inhibitors. Belimumab was approved by the U.S. Fo...]]></description><category>Uncategorized</category><guid isPermaLink="false">1702845_NEWS</guid><pubDate>Tue, 05 Jun 2012 22:05:15 GMT</pubDate></item><item><title>Human Genome Sciences Invites Investors to Listen to Webcast of Presentation at Goldman Sachs Conference</title><link>http://phx.corporate-ir.net/phoenix.zhtml?c=83257&amp;p=RssLanding&amp;cat=news&amp;id=1701921</link><description><![CDATA[    ROCKVILLE, Md.--(BUSINESS WIRE)--Jun. 4, 2012--
      Human Genome Sciences, Inc. (NASDAQ: HGSI) announced today that its
      presentation at the Goldman Sachs 33rd Annual Global Healthcare
      Conference will be webcast and may be accessed at www.hgsi.com.
    

      A member of Human Genome Sciences’ senior management team will present a
      corporate overview on Tuesday, June 5, 2012, at 5:40 PM Eastern time.
      Investors interested in listening to the live webcast may want to log on
      before the presentation begins to download any software required. The
      archive of the presentation will be available for several days following
      the event.
    

  ...]]></description><category>Uncategorized</category><guid isPermaLink="false">1701921_NEWS</guid><pubDate>Mon, 04 Jun 2012 10:30:51 GMT</pubDate></item><item><title>Human Genome Sciences Response to GSK Press Release</title><link>http://phx.corporate-ir.net/phoenix.zhtml?c=83257&amp;p=RssLanding&amp;cat=news&amp;id=1701725</link><description><![CDATA[    ROCKVILLE, Md.--(BUSINESS WIRE)--Jun. 1, 2012--
      Human Genome Sciences, Inc. (Nasdaq: HGSI) today issued the following
      statement in response to the GlaxoSmithKline plc (GSK) announcement
      regarding expiration of the Hart-Scott-Rodino waiting period:
    

      “The HGS Board of Directors has rejected GSK’s unsolicited $13.00 per
      share offer, after concluding unanimously that the GSK offer is
      inadequate, does not reflect the value inherent in HGS and is not in the
      best interests of our stockholders. We announced on April 19 that our
      Board has authorized the exploration of strategic alternatives in the
      best interests of stockholders...]]></description><category>Uncategorized</category><guid isPermaLink="false">1701725_NEWS</guid><pubDate>Fri, 01 Jun 2012 17:37:46 GMT</pubDate></item></channel></rss>